Efficacy data for Fabre-Kramer Pharmaceuticals Inc.'s gepirone in major depressive disorder fall short of the evidentiary standard needed for approval, an FDA advisory committee said Dec. 1.
In two separate 9-4 votes, the majority of Psychopharmacologic Drugs Advisory Committee members said Fabre-Kramer had not provided substantial evidence of effectiveness for gepirone extended-release, and